MarginsXMarginsX
Home › Markets › Health Care › CVM

Cel-Sci Corporation (CVM)

CVM trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.66
+29.69% on the day
Market cap
$29.2M
Nano cap
Revenue
No annual revenue filed since the period ending 2014-09-30
Net income
No annual revenue filed since the period ending 2014-09-30

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerCVM on NYSE
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year1997
SEC CIK0000725363
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inCO

Financials

No annual revenue filed since the period ending 2014-09-30.

Warning signs

Cash runway
4.7 months
$6.5M cash at June 30, 2026
Share count, 1 year
+155.6%
2025-08-13 to 2026-08-10 · +1016.5% over 3 years
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$867K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-08-14
Cash and burn$6.5M cash; operating cash flow -$4.2M a quarter.Report 2026-06-30
Shares outstanding17,588,987 (2026-08-10); 6,882,156 a year earlier; 47,260,097 three years earlier. 3y figure adjusted for splits (1-for-30 overall).Cover page 2026-08-10
Reverse splits, 3 years1; latest 1-for-30 on 2025-05-20Source 2025-05-20
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-06-15
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBDO USA, P.C., Potomac, Maryland, United StatesPCAOB Form AP 2025-12-29
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $867K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-06-30
Not filed-$5.7M-$4.0M$6.5MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q2 2026
2026-03-31
Not filed-$5.5M-$4.0M$1.9MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2026
2025-12-31
Not filed-$5.5M-$4.0M$6.3MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2025
2025-09-30
Not filed-$6.1M-$4.7M$11.0M$8.0MNeeds four quarters10-K 2025-12-29
Q3 2025
2025-06-30
Not filed-$5.7M-$3.9M$1.8MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q2 2025
2025-03-31
Not filed-$6.6M-$4.4M$1.9MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2025
2024-12-31
Not filed-$7.1M-$4.1M$4.6MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2024
2024-09-30
Not filed-$6.1M-$4.8M$4.7MNo debt tagsNeeds four quarters10-K 2025-12-29

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM 424B5
424B52026-06-15
Latest annual report
FORM 10-K
10-K2025-12-29
Latest quarterly / interim
FORM 10-Q
10-Q2026-08-14
Latest current report
FORM 8-K
8-K2026-08-17
Latest proxyDEF 14A2026-07-02

Source: SEC EDGAR submissions feed, 1,007 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-11.7%
1 month-26.9%
3 months-14.1%
Year to date-75.7%
1 year-80.7%
From 52-week high-83.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
INMBINmune Bio Inc.$0.9464-9.87%$29.3M
SAENGenenta Science S.p.A.$0.6000-7.66%$28.9M
PTHSPelthos Therapeutics Inc.$7.15-3.90%$28.1M
LONALeonaBio Inc.$3.23-6.92%$30.4M
MGXMetagenomi Therapeutics Inc.$0.6800-1.69%$25.7M
EVAXEvaxion A/S American Depositary Share$2.77+0.54%$25.5M
KLRSKalaris Therapeutics Inc.$1.46-7.30%$34.8M
ELUTElutia Inc.$0.8229+0.35%$36.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier